Status:
COMPLETED
A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea
Lead Sponsor:
Boehringer Ingelheim
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of this study is to monitor the safety profile of Trajenta Duo in Korean patients with type 2 diabetes mellitus (T2DM) in a routine clinical setting.
Detailed Description
Study Design: Post Marketed Study- Observational study
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Potential subjets must meet all of the following inclusion criteria to enter this trial:
- No previous exposure to Trajenta, Trajenta Duo
- Should have been started on Trajenta Duo in accordance with the approved label in Korea
- No current participation in clinical trials
- No metformin is inappropriate due to contraindications
- Must sign on the data release consent form
- Exclusion criteria:
- Individuals with any of the following characteristics will not be able to enter this study:
- Previous exposure to Trajenta, Trajenta Duo
- Current participation in clinical trials
- Patients for whom metformin is inappropriate due to contraindications
Exclusion
Key Trial Info
Start Date :
July 11 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 10 2017
Estimated Enrollment :
724 Patients enrolled
Trial Details
Trial ID
NCT01903356
Start Date
July 11 2013
End Date
June 10 2017
Last Update
December 21 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, South Korea